Novavax shared positive initial results from the Phase I/II clinical study of the company’s proposed combination vaccine for COVID-19.

Moderna’s CEO Stéphane Bancel spoke at the Boston College Chief Executives Club on April 5. While COVID-19 vaccine production was a big talking point for the leader of Moderna, he also touched on how mRNA technology can usher us into a longer life span, saying that he tells all of his friends to “not die” in the next ten years.

People who die of severe COVID-19 have brain abnormalities that resemble changes seen in Alzheimer’s disease – accumulation of a protein called tau inside brain cells, and abnormal amounts of the protein beta-amyloid that accumulates into amyloid plaques – small studies found. In other news, seniors can safely get the high-dose flu vaccine and an mRNA COVID-19 booster dose at the same time, a new study confirms.

Moderna is poised to commercialize the company’s COVID-19 and influenza combination vaccine by the fall of 2023, with some potential for the same drug to also be viable against respiratory syncytial virus (RSV). 

Moderna Inc. executives called on investors to wait for more data amid a sharp selloff in the company’s shares on Friday, after early data showed its mRNA-based flu vaccine was no better than already approved shots in the market.

A new study shows that there might be a way to protect against influenza infection without needing to stir up antibody response.

People can get inoculated against Covid-19 and the seasonal influenza at the same time without compromising the vaccines’ effectiveness, a World Health Organization official said on November 4.

The U.S. Food and Drug Administration approved Seqirus’ Flucelvax Quadrivalent (Influenza Vaccine), the company’s cell-based quadrivalent influenza vaccine, for an expanded age indication for children as young as 6 months old.

Moderna Inc. is developing a single vaccine that combines a booster dose against Covid-19 with the company’s experimental flu shot.

Vaccine developer Novavax Inc. said on Sept. 8 the company initiated an early-stage study to test a combination of the flu shot NanoFlu and the Covid-19 vaccine NVX-CoV2373.